REFRACTORY IMMUNE-RELATED CYTOPENIA

Clinical trials for REFRACTORY IMMUNE-RELATED CYTOPENIA explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY IMMUNE-RELATED CYTOPENIA trials appear

Sign up with your email to follow new studies for REFRACTORY IMMUNE-RELATED CYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New combo therapy aims to tame stubborn blood disorders

Disease control Not yet recruiting

This early-stage study tests whether combining two drugs (a CD20 antibody and a BTK inhibitor) can help people with refractory immune-related cytopenia—conditions where the immune system attacks blood cells, causing low platelets (ITP) or anemia (AIHA). About 30 adults aged 18-80…

Matched conditions: REFRACTORY IMMUNE-RELATED CYTOPENIA

Phase: PHASE1 • Sponsor: Qi deng • Aim: Disease control

Last updated May 09, 2026 05:33 UTC

REFRACTORY IMMUNE-RELATED CYTOPENIA

Get alerted when new REFRACTORY IMMUNE-RELATED CYTOPENIA trials appear

New combo therapy aims to tame stubborn blood disorders